Vancomycin serum concentration monitoring. The middle ground is best

Clinical Drug Investigation

Volumn 12, Issue 2, 1996, Pages 105-118

  Marra, F ^a   Cairns, B ^b   Jewesson, P ^a,b  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSAY; BODY WEIGHT; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOXICITY; FEMALE; HUMAN; INDIVIDUALITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OTOTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT;

EID: 0029840254     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199612020-00006     Document Type: Article

References (81)

1. Cunha BA, Ristuccia AM. Clinical usefulness of vancomycin. Clin Pharm 1983; 2: 417-24
2. Louria DB, Kaminski T, Buchman J. Vancomycin in severe staphylococcal infections. Arch Intern Med 1961; 107: 225-40
3. Woodley DW, Hall WH. The treatment of severe staphylococcal infections with vancomycin. Ann Intern Med 1961; 55: 235-49
4. Downs NJ, Neihart RE, Dolezal JM, et al. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149: 1777-81
5. Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991; 115: 739-41
6. Cheung RPF, DiPiro JT. Vancomycin: an update. Pharmacotherapy 1986; 6: 153-69
7. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting proof of its value. Clin Pharm 1987; 6: 652-4
8. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-43
9. Shafran SD, Conly JM. The serum vancomycin assay: a test of historic interest. Can J Infect Dis 1995; 6: 67-8
10. Moellering RC. Monitoring serum vancomycin levels: Climbing the mountain because it is there? Clin Infect Dis 1994; 18: 544-6
11. Shalansky S. Rationalization of vancomycin serum concentration monitoring. Can J Hosp Pharm 1995; 48: 17-24
12. Conly JM, Gold W, Shafran SD. Once-daily aminoglycoside dosing: a new look at an old drug. Can J Infect Dis 1994; 5: 905-6
13. Peck CC, Rodman JH. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimens. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: Principles of therapeutic drug monitoring, 2nd ed. Spokane: Applied Therapeutics 986: 55-82
14. Matzke GR. Vancomycin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: Principles of therapeutic drug monitoring, 2nd ed. Spokane: Applied Therapeutics 986: 399-436
15. Pfaller MA, Krogstad DJ, Granich GG, et al. Laboratory evaluation of five assay methods of vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay. J Clin Microbiol 1984; 20: 311-6
16. Ackerman BH, Berg HG, Strate RG, et al. Comparison of radioimmunoassay and fluorescent polarization immunoassay for quantitative determination of vancomycin concentrations in serum. J Clin Microbiol 1983; 18: 994-5
17. Filburn BH, Shull VH, Tempera YM, et al. Evaluation of an automated fluorescence polarization immunoassay for vancomycin. Antimicrob Agents Chemother 1983; 24: 216-20
18. Schwenzer KS, Wang CJ, Anhalt JP, et al. Automated fluorescence polarization immunoassay for monitoring vancomycin. Ther Drug Monit 1983; 5: 341-5
19. Pohlad DJ, Saravolatz LD, Somerville MM. Comparison of fluorescence polarization immunoassay and bioassay of vancomycin. J Clin Microbiol 1984; 20: 159-61
20. Healy DP, Polk RE, Garson ME, et al. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal healthy volunteers. Antimicrob Agents Chemother 1987; 31: 393-7
21. Healy DP, Sahai JV, Fuller SH, et al. Vancomycin induced histamine release and 'red man syndrome': comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother 1990; 34: 550-4
22. Banner W, Ray CG. Vancomycin in perspective. Am J Dis Child 1984; 138: 14-6
23. Moellering RC. Pharmacokinetics of vancomycin. J Antimicrob Agents Chemother 1984; 14: Suppl. D: 43-52
24. Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25: 433-7
25. Moellering RC, Krogstad DJ, Greenblatt DJ. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis 1981; 3 Suppl.: S230-235
26. Rotschafer JC, Crossley K, Zaske DE, et al. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agenis Chemother 1982; 22: 391-4
27. Moellering RC, Krogstad DJ, Greenblatt DJ, et al. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94: 343-6
28. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32: 848-52
29. Cutler NR, Narang PK, Lesko LJ, et al. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984; 36: 803-10
30. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994; 16: 513-8
31. Schaad UB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119-26
32. Gross JR, Kaplan SL, Kramer WG, et al. Vancomycin pharmacokinetics in premature infants. Pediatr Pharmacol 1985; 5: 17-22
33. Spivey JM, Gal P. Vancomycin pharmacokinetics in neonates. Am J Dis Child 1986; 140: 859
34. Naqvi SH, Keenan WJ, Reichley RM, et al. Vancomycin pharmacokinetics in small, seriously ill infants. Am J Dis Child 1986; 140: 107-10
35. Schaible DH, Rocci ML, Alpert GA, et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Ped Infect Dis 1986; 5: 304-8
36. Reed MD, Kliegman RM, Weiner JS, et al. The clinical pharmacology of vancomycin in seriously ill preterm infants. Ped Res 1987; 22: 360-3
37. James A, Koren G, Milliken J, et al. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987; 31: 52-4
38. Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994; 56: 169-75
39. Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35: 637-42
40. Leonard AE, Boro MS. Vancomycin pharmacokinetics in middle-aged and elderly men. Am J Hosp Pharm 1994; 51: 798-800
41. Guay DR, Vance-Bryan K, Gilliland S, et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993; 33: 918-22
42. Macias WL, Mueller BA, Scarim SK, et al. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 1991; 50: 688-94
43. Fernandez de Gatta MM, Fruns I, Dominguez-Gil A. Individualizing vancomycin dosing regimens: an evaluation of two pharmacokinetic dosing programs in critically ill patients. Pharmacotherapy 1994; 14: 196-201
44. Garaud JJ, Regnier B, Inglebert F, et al. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother 1984; 14 Suppl. D: 53-7
45. Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988; 44: 9-13
46. Brater DC, Bawdon RE, Anderson SA, et al. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 1986; 39: 631
47. Cairns B, Jewesson P. Vancomycin disposition in leukemic patients. Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract 1337]. ICAAC, Houston, Texas, 1989
48. Cairns B, Jewesson PJ. Vancomycin. Vancouver General Hospital Drug Information Supplement 1990; 7: 1-4
49. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
50. Nimmo CR, Mamdani F, Baker A, et al. Development and implementation of simplified aminoglycoside empiric dosing guidelines. Pharmacotherapy 1993; 13: 408-14
51. Vance-Bryan K, Guay DR, Gilliland SS, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37: 436-40
52. Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-80
53. Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Part IV: vancomycin. Clin Pharmacokinet 1991; 20: 463-76
54. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic monitoring: is it necessary? Ann Pharmacother 1993; 27: 594-8
55. Sorrell TC, Packham DR, Shanker S, et al. Vancomycin therapy for methicillin resistant Staphylococcus aureus. Ann Intern Med 1982; 97: 344-50
56. Viladrich PF, Gudiol F, Linares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35: 2467-72
57. Cafferkey MT, Hone R, Keane CT. Severe staphylococcal infections treated with vancomycin. J Antimicrob Chemother 1982; 9: 69-74
58. Leader WG, Chandler MH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327-42
59. Peetermans WE, Hoogeterp JJ, Hazekamp-Van Dokkum AM, et al. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990; 34: 1869-74
60. Watanakunakorn C. The antibacterial action of vancomycin. Rev Infect Dis 1981; 3 Suppl.: S210-215
61. Tuazon CU, Miller H. Comparative in vitro activities of teicoplanin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci. Antimicrob Agents Chemother 1984; 25: 411-2
62. Uttley AHC, Collins CH, Naidoo J, et al. Vancomycin-resistant enterococci. Lancet 1988; 1: 57-8
63. Shlaes DM, Binczewski B, Rice LB. Emerging antimicrobial resistance and the immunocompromised host. Clin Infect Dis 1993; 17 Suppl.: S527-536
64. Handwerger S, Perlman DC, Altarac D, et al. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis 1992; 14: 655-61
65. Hayden M, Koenig G, Harris A, et al. Emergence of high-level vancomycin resistance in enterococci from two neighbouring hospitals. [abstract no. 984]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1991
66. Livornese LL, Dias S, Samel C, et al. Hospital acquired infection with vancomycin resistant Enterococci fecium transmitted by electronic thermometers. Ann Intern Med 1992; 117: 112-6
67. Geraci JE, Heilman FR, Nichols DR, et al. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Mayo Clin Proc 1956; 31-564-82
68. Redfield D, Underman A, Norman D, et al. CSF penetration of vancomycin In bacterial meningitis. In: Nelson JD, Grassi C, editors. Current chemotherapy and infectious disease proceedings. 11th ICC and 19th ICMC, 1980; 1: 628-40
69. Nolan CM, Flanigan WJ, Rastogi SP, et al. Vancomycin penetration into CSF during treatment of patients receiving haemodialysis. South Med J 1980; 73: 1333-8
70. Massias L, Dubois C, DeLentdecker P, et al. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 1992; 36: 2539-41
71. Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138-41
72. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-87
73. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325-34
74. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteraemia. Pharmacotherapy 1995; 15: 85-91
75. Cimino MA, Rotstein C, Slaughter RL, et al. Relationship of serum antibiotic concentrations to nephrotoxicity in hematology patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987; 83: 1091-7
76. Pauly DJ, Musa DM, Lestico MR, et al. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990; 10: 378-82
77. Rodvold KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987; 6: 655-8
78. Lake KD, Peterson CD. Evaluation of a method for initiating vancomycin therapy: experience in 205 patients. Pharmacotherapy 1988; 8: 284-6
79. McCormack JP, Lynd LD, Pfeifer NM. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service. Can J Hosp Pharm 1989; 42: 3-9
80. Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994; 28: 1335-9
81. McCormack JP, Jewesson PJ. A critical reevaluation of the 'therapeutic range' of aminoglycosides. Clin Infect Dis 1992; 14: 320-39